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ABSTRACT
AITKEN,CHELSEA Biological activity of a set of new copper(II)
complexes: toward understanding structure-reactivity correlations

ADVISOR: Professor Laurie A. Tyler
Cisplatin, carboplatin and oxaliplatin are all platinum-containing complexes that
have been approved for use as chemotherapy drugs. The success of these complexes as
well as their downfalls have sparked interest into alternative transition metal based
compounds as potential chemotherapeutic agents. The use of platinum based complexes
in cancer treatment has faced complications including cytotoxicity and drug resistance.
The use of copper(II) as an alternative metal center is of specific interest because of
bioavailability and elevated concentrations of this metal ion within tumor cells. Three
copper complexes that utilize a nitrogen based ligand system, two of which contain a
thiazole moiety have been synthesized and characterized. The biological activity and
potential cytotoxicity of these complexes was measured on the basis of nuclease activity,
DNA binding, and interaction with BSA. These characteristics were determined by
quantitative analysis of studies using ethidium bromide, gel electrophoresis, and UV-Vis
spectroscopy. It has been shown that all of these complexes exhibit concentration
dependent nuclease activity utilizing a mechanism dependent on reactive oxygen species.
Here, comparisons between the activity of these newly synthesized compounds and those
previously studied are presented to aid in developing a correlation between ligand
structure and complex activity.
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1. Introduction
The American Cancer Society estimated that in the U.S. 1,638,910 new cases of
cancer were diagnosed in 2012 alone and 577,190 cancer related deaths occurred.1 These
numbers demonstrate the prevalence of cancer and highlight the great impact it has on
our lives. Most of our lives have been touched by cancer in some way, whether as the
patient, a family member, or a friend. Research in this field is ongoing and of extreme
importance.

In humans, all the cells within a tumor are believed to originate from a single cell
that was converted from a normal cell to a cancerous cell. This type of cancer origination
is named monoclonal, the other possibility (polyclonal origination) has not been observed
in humans.2 The next question then becomes how does a cell convert from a normal cell
to a cancerous one. Cancer occurs once multiple mutations have been sustained and
propagated. Often these mutations are specific to genes responsible for regulating cell
cycle control, allowing the cancerous cells to proceed through the cell cycle and produce
progeny despite sustained mutations.2 Typically a single mutation, particularly in an
essential gene, will promote a cell to undergo programmed cell death preventing the
spread of that mutation to subsequent generations of cells. However, some mutations are
not repaired in time and in many cases with pre-cancerous mutations the mutated gene
actually allows the daughter cells to be more susceptible to sustaining subsequent
mutations because the initially mutated gene was involved in a pathway responsible for
cell division control or DNA damage monitoring.2,3 Cancer is not really a single disease,
but rather many diseases with one unifying factor, the ability of cells to proliferate
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without regulation.3 A tumor is a mass of these mutated cells that are dividing without
regulation and the tumor is considered malignant once the cancerous cells begin to invade
tissues outside of their native region in the body. Cancers can be divided into four
predominant types: carcinomas, sarcomas, leukemia, and lymphoma.3

1.1 Inducing programmed cell death in cancerous cells
Apoptosis is a form of highly controlled internally initiated cell death. Various
factors, intracellular and extracellular, can be responsible for triggering this response in
cells. This type of cell death is advantageous because the cell shrinks and then breaks
into membrane enclosed fragments, which can later be digested without any harm to
surrounding cells.4,5 There are three circumstances under which apoptosis typically occur.
The first involves apoptosis initiated by environmental factors, such as limited physical
space or cellular resources this is termed utilitarian cell suicide, because a perfectly
healthy cell undergoes cell death for the overall benefit of the surrounding cellular
population.4 This is specifically useful during development. Apoptosis can also be
triggered in cells once they have reached or surpassed their cellular life expectancy; this
is called senescent cell suicide.4 Finally, the situation that triggers apoptosis that is most
relevant to our discussion of cancer and cancer treatments, involves the initiation of
apoptosis due to cellular damage. Damage to DNA, cellular membranes, or other vital
cellular components induces the cell to initiate programmed cell death rather than risk
incorrectly repairing the damage and propagating it to subsequent generations.4
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There is a strong correlation between genes involved in the apoptotic pathway and
cancer. Tumor suppressor genes are typically involved in controlling proliferation and do
so by acting as signals in control pathways including apoptosis, cell cycle, and DNA
repair. Genes are considered tumor suppressors not only because they are essential in
these types of pathways, but also because their absence has been shown to promote
cancer.5 p53 is one of the quintessential tumor suppressor genes and a mutation in this
gene is found in the majority of all human tumors.6 In healthy cells, p53 accumulates in
response to cellular stress, such as extensive DNA damage, and then functions as an
activator in the apoptotic pathway. Mutations in the genes responsible for encoding p53
result in cells that evade apoptosis and survive despite damage that should cause them to
initiate programmed cell death.5 This type of mutation is advantageous for cancerous
cells because in order to proliferate without control in non-native environments they need
to evade checkpoints that function to kill cells with these characteristics. Several other
oncogenes have been discovered that are a part of the apoptotic pathway. The protein
Bcl-2 is known to act as an anti-apoptosis signal and is often over expressed in cancerous
cells. Some oncogenes are actually responsible for promoting apoptosis, one example is
Myc which functions as both a promoter of cell proliferation and a promoter of
apoptosis.5 This dual functionality is a useful control in healthy cells because it ensures
that cells need both an activating signal from Myc and an anti-apoptotic signal in order to
continue proliferating. However, in the presence of consistent anti-apoptosis signals such
as when bcl-2 is overexpressed, the proliferating activity of Myc continues to be active
allowing the cells to continuously divide without initiating cell death.5
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Even though apoptotic pathways are often malfunctioning in cancerous cells, the
induction of apoptosis is an important aim of many cancer treatments. The complex
relationship between tumor development and alterations of the cells’ ability to initiate
programmed cell death makes apoptosis an interesting target for cancer treatments; the
goal is to trigger apoptosis more readily in the mutated cells than in the patients’ healthy
cells.7 Tumors with mutations in genes such as p53 have increased risk of being resistant
to these treatments because of their inactivated apoptotic pathways. On the other hand,
tumors that have activated oncogenes such as Myc are often more receptive to treatment
because apoptosis can be triggered more easily.5 Chemotherapeutic drugs that induce
apoptosis in tumor cells also promote apoptosis in healthy cells, which is one of the
causes of cytotoxicity and other negative side effects experienced with chemotherapy.6
Some current studies are focusing on designing chemotherapy drugs that target specific
effector molecules within the apoptosis pathway, however historically many successful
chemotherapy drugs have the simple aim of damaging DNA in order to promote
apoptosis. It is important to note that inflicting DNA damage on cancerous cells also has
the ability to promote other types of cell death such necrosis, mitotic catastrophe,
autophagy, and early senescence. Historically a focus had been placed on apoptosis,
however the ability to selectively induce cell death in any capacity is a promising
characteristic of any potential anti-cancer agent.8

1.2 Cancer treatments currently available and how they function
For the most part cancer treatments fall into three main categories: surgery,
radiation, and chemotherapy. Many cancer treatment plans involve the use of two or
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more of these treatments administered either simultaneously or in succession.9 Surgery is
typically used for cancers that are isolated and have yet to metastasize. In this case the
goal of surgery is to remove the entirety of the tumor and sometimes radiation or
chemotherapy is administered post operatively to kill off any cancerous cells the surgery
may have missed. Alternatively, surgery can be used to reduce the size of a large tumor
that cannot be removed entirely before starting radiation or chemotherapy to increase the
chances of success with one of these treatments.9 Radiation therapy uses X-rays to
eliminate tumors. The concept behind this treatment is that the X-rays will induce DNA
damage within the exposed cells and the actively dividing mutated cancer cells will be
less able to repair this damage than healthy cells, promoting an increased rate of cell
death in the cancerous cells. Since this treatment relies on damaging DNA there is a
small risk that a patient will develop a different cancer as a result of receiving radiation
therapy.9

The final category of available treatment options is chemotherapy, which actually
encompasses a wide range of cytotoxic drugs that work by inhibiting cellular growth or
promoting cell death. One of the benefits of this type of treatment is the fact that it’s
systemic so it can be used for cancers that are not tumorous and those that have
metastasized before they have formed masses large enough to detect.9 Since the aim of
these drugs is to disrupt cell proliferation the target of their activity is often DNA,
because the cells need functional DNA in order to replicate and proceed through the cell
cycle. Some of these agents work by altering the structure of DNA bases thus limiting
reactivity of enzymes involved in replication, some work by creating crosslinks between
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the bases so that they cannot be separated and others are successful by causing breaks on
one or both strands in the double helix.9

1.3 Metal complexes as chemotherapy agents
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Figure 1. Structures
of cisplatin, carboplatin, and oxaliplatin. (Figures taken from Clinical Status
of Cisplatin, Carboplatin, and Other Platinum-Based Antitumor Drugs13)
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machinery.10,11 Once
cisplatin crosses the membrane and enters a cell it is surrounded by
Carboplatin
an aqueous environment with a lower chloride concentration; as a result one of the
chloride groups is typically replaced with a water molecule. After water has bound to
cisplatin, the complex becomes a positively charged species that is highly reactive with
DNA’s negatively charged backbone.10 Cisplatin is known to preferentially bind with
deoxyguanosines and create interstrand, intrastrand, and DNA-protein cross-linkages.

6

O

Interstrand cross-linkages result from one cisplatin binding to two bases on opposite
strands of the double helix, whereas intrastrand cross-linkages result from binding to two
bases on the same strand. These alterations of the DNA, shown in Figure 2, are thought to
be the main source of cisplatin’s cytotoxicity because the damage often induces
apoptosis.10,11 Radio-labeling has shown that the majority of linkages formed are
intrastrand and it is generally accepted that these linkages contribute most to cisplatin’s
overall cytotocity.12,13 Due to the damage interrupting DNA replication, the cytotoxicity
is specific to rapidly dividing cells, such as cancerous ones. Cisplatin has been used to
effectively treat testicular, ovarian, lung, head, neck, and bladder cancers.14 Although the
success of cisplatin has made great improvements in cancer treatment and survival, it is
also linked to a number of negative side effects including nephrotoxicity and
neurotoxicity. As a result, the search for cisplatin analogs that are less toxic to healthy
cells and ultimately less damaging to the patient continues to be at the forefront of
research efforts.

Figure 2. Structure of interstrand and intrastrand adducts on DNA caused by cisplatin.
(Figures taken from: The Mechanism of Action of Cisplatin: From Adducts to Apoptosis 11)

Carboplatin was designed as a cisplatin analog. The design behind the synthesis

7

of this drug was replacing the labile chloride groups in cisplatin with more stable ligands
in an effort to lower the overall toxicity of the compound, in order to minimize negative
effects on healthy cells. As hoped, carboplatin proved less toxic than cisplatin and has
similar effectiveness as an anti-cancer drug by causing similar adducts on DNA.14

Oxaliplatin is a cisplatin analog that not only has more stable ligands in place of
chloride groups, but also has diaminocyclohexane in place of the two amine groups.
Similarly to cisplatin, this anti-cancer agent is known to function by inducing three
different types of crosslinks on DNA: intrastrand, interstrand, and DNA-protein. As with
the other complexes these crosslinks serve to arrest the cell cycle and eventually promote
apoptosis. Although the main mode of inflicting DNA damage seems to be the same, the
structural differences have allowed oxaliplatin to be useful in the treatment of digestive
system cancers, which are untreatable with cisplatin and carboplatin.15

Although these three platinum containing compounds have been successful in
treating certain types of tumors, their usage faces certain restrictions. These obstacles
include cells building resistance to platinum-based anti-cancer drugs, the toxicity of the
metal having negative impacts on the rest of the body, and an insufficient amount of
uptake by the cell. Some studies have used the properties of copper in order to aid the
transport of platinum-based complexes, because specific channels exist to allow its
transport into the cell.16
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1.4 Copper based compounds as potential chemotherapeutic agents
Copper is naturally occurring in the body and its role in redox chemistry makes it
an essential element needed for many basic biochemical reactions. Ideally the
bioavailability of copper will result in lower toxicity levels of copper containing anticancer complexes compared to other non-essential transition metals such as platinum.17
Additionally, it has been found that copper concentrations are elevated in tumors and its
presence is thought to be essential for angiogenesis.18 Overall, copper complexes show
great potential as anti-cancer agents because the metal involved may be selectively
shuttled to cancerous masses within the body.

The reactivity of copper complexes is assessed by DNA cleavage, protein binding,
and DNA binding. Previously, in the Tyler research group utilized ligand frames
Project Description
containing substituted thiazole groups, specifically where R= 8-hydroxyquinoline, 2The goal of my project will be to synthesize new Cu(II) based ligand complexes by altering the
pyridine, and 2-quinoline. The synthetic scheme for these ligands is shown in Figure 3.
thiazole based ligand system. The general reaction for the synthesis of the thiazole ligand is shown in
Figure 1.

Figure 1. Reaction for thiazole ligand compounds, where R represents the groups being altered.
Figure 3. Reaction for thiazole ligand compounds, where R represents the groups being
altered.
Previously, in the Tyler research group, R = 8-hydroxyquinoline has been synthesized and the
corresponding Cu(II) complexes isolated and characterized. This complex has been assessed for
9

biological activity including DNA binding and cleavage studies.

Several corresponding Cu(II) complexes with these ligands have been isolated
and characterized. The complexes shown in Figure 4 were tested for biological activity
by lab members Han Lin and David Foreman.19,20 These complexes were assessed for
biological activity using the aforementioned criteria DNA binding, protein binding, and
DNA cleavage.
1

2

3

4

Figure 4. Crystal structures of Cu(8OHQ(oBt))Cl2 (1) Cu(8OQ(oBt))Cl (MeOH) (2)
Cu(Q(oBt))(H2O)(NO3)2 (3) and [Cu(Py(oBt))2H2O]2+(BF4)2 (4) 19.20

Studies of the compounds shown in Figure 4 demonstrated that the structural
differences between them influenced their efficiency for DNA cleavage and the strength
of DNA binding. DNA cleavage studies indicated that compound 2 had the greatest DNA
cleavage efficiency while compound 4 had the least efficiency. DNA binding studies
using EtBr indicated that compound 1 intercalates DNA with the greatest strength and
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compound 4 intercalates with the least strength. Protein binding studies did not provide
comparative results because binding constants were not determined.19

This project is an extension of the aforementioned work. I have synthesized new
thiazole based ligands and the corresponding copper complexes. These complexes have
been tested for biological activity in the same manner as those previously studied and
reactivity and binding strength comparisons have been made between all the complexes
tested up to this point.

2. Experimental
2.1 Material

All starting materials were purchased from Sigma Aldrich and were used in their
original condition without further purification. Anhydrous solvents were also purchased
from Sigma Aldrich and left untreated.

2.2 Instruments
H1 NMR spectra were collected using a 400 MHz Brüker Avance NMR
spectrometer. Infrared spectra were collected using a Nicolet Avatar 330 FT-IR with
smart orbit solid-state attachment. Absorbance spectra were obtained using an Agilent
8453

spectrophotometer.

Fluorescence

spectra

were

collected

using

an

810

Photomultiplier Detection System spectrophotometer. A Bio Rad PowerPac 300 was used
for DNA separation via agarose gel electrophoresis. Gel images were recording using a
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Syngene

G:Box

and

analysis

of

band

density

was

performed

using

the

Syngene:GeneTools program.

2.3 Preparation of Ligands
2.3.1 PyOMe(oBt)
The ligand, PyOMe(oBt), was synthesized in the following way: 346 µL (2.88
mmol) of 6-methoxy-2-pyridine carboxaldehyde and 308 µL (2.88 mmol) of 2aminothiophenol were added to ~20 mL of ethanol (EtOH). The reaction was refluxed
for 1 h. After refluxing, the solution was left to heat open to air for an additional hour, as
a result the volume was reduced to ~5 mL via evaporation and a white precipitate formed.
The product was collected via vacuum filtration, washed with EtOH, and then dried
under vacuum for 1 h. Yield: 755 mg (47%). 1H NMR (CDCl3, 400 MHz, 25º C, δ from
TMS): 8.08 (d, 1H, J = 8.16 Hz), 7.95 (m, 2H), 7.728 (m, 1H), 7.50 (m, 1H), 7.40 (m,
1H), 6.86 (d, 1H, J = 8.24 Hz), 4.07 (s, 3H). Selected IR bands: (cm-1) 1574 (νN=C), 1421
(s), 724 (s), 801 (m).

2.3.2 PyOMe(en)
The ligand, PyOMe(en), was synthesized in the following way: 720 µL (5.98
mmol) of 6-methoxy-2-pyridine carboxaldehyde and 200 µL (2.99 mmol) of ethylene
diamine (en) were added to ~30 mL of EtOH. The reaction was refluxed for 1 h resulting
in a color change to bright yellow. The solution volume was then reduced to ~10 mL via
rotoevaporation resulting in the formation of a white solid. The product was collected via
vacuum filtration, rinsed with hexanes, and then dried under vacuum for 1 h. Yield: 311.4
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mg (49%). 1H NMR (CDCl3, 400 MHz, 25º C, δ from TMS): 8.30 (s, 1H), 7.58 (m, 2H),
6.76 (d, 1H, J = 7.72 Hz), 4.02 (s, 2H), 3.95 (s, 3H). Selected IR bands: (cm-1) 1587
(νN=C), 1019(m), 730 (s).

2.4 Synthesis of Complexes
2.4.1 Cu(PyOMe(oBt))Cl2 (1)
First, the ligand PyOMe(oBt) (260.9 mg, 1.10 mmol) was dissolved in ~10 mL
MeOH. Separately, copper chloride (185.8 mg, 1.10 mmol) was dissolved in ~5 mL
MeOH. Next, the metal solution was added dropwise to the ligand solution. The solution
turned a deep brown color upon addition of the metal salt. The solution was stirred for 24
h and then gravity filtered. Upon slow diffusion of diethyl ether (Et2O) into this brown
solution resulted in the formation of, orange-brown, block like crystals. Yield: 166 mg
(17.1%). Selected IR bands: (cm-1) 1573 (νN=C), 1429 (s), 732 (s), 806 (m). Electronic
absorption spectrum in MeOH: λmax (nm) (ε, M-1 cm-1) 322 (40213).

2.4.2 [Cu(PyOMe(oBt)2(NO3)]NO3 (2)
Ligand, PyOMe(oBt) (192.7 mg, 0.82 mmol) and copper nitrate (95.2 mg,
0.41mmol) were separately dissolved in ~10 mL of methanol (MeOH). Next, the metal
was added dropwise to ligand. Upon addition of the metal the solution turned brownyellow and a lime green solid formed almost immediately. The solution was allowed to
stir for 6 h and then gravity filtrated. Upon slow diffusion of acetonitrile (ACN), the
brown solution turned a bright green color similar to the initial solid collected. The
solution was then left to slowly evaporate. After several days large green block like
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crystals had formed. Yield: 62.8 mg (27.5%). Selected IR bands: (cm-1) 1427 (s), 728 (s),
808 (m). Electronic absorption spectrum in MeOH: λmax (nm) (ε, M-1 cm-1) 322 (34194).

2.4.3 [Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4 (3)
First, the ligand PyOMe(en) (217.8 mg, 0.73mmol) was dissolved in ~10 mL
anhydrous MeOH then copper nitrate (169.8 mg, 0.73mmol) was separately dissolved in
~10 mL anhydrous MeOH. Next, the metal solution was added dropwise to the ligand
solution. The colorless solution turned a deep aqua color upon addition of the metal
solution. The solution was stirred for 24 h and then gravity filtered. Upon slow diffusion
of Et2O into the solution, deep blue crystals formed. Yield: 45.5 mg (19.1%). Selected IR
bands: (cm-1) 1592 (νN=C), 999(m), 732 (s).

2.5 Solution Preparations
2.5.1 TAE Buffer (1X)
50X TAE Buffer was prepared at outlined in Fox Research Lab Protocols.21 20
mL of the 50X buffer was then diluted to a final volume of 2 L with deionized water.

2.5.2 Tris-HCl Buffer (5 mM Tris, pH 7.2) 50 mM NaCl
First, Tris (151.4 mg) was dissolved in ~ 200 mL of deionized water and then
NaCl (730 mg) was also added into the solution. The desired pH was reached by titrating
with 0.1M HCl and/or 0.1M KOH while monitoring the solution using a pH electrode.
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Once a pH reading of 7.2 was reached the solution was diluted to a final volume of 250
mL with deionized water in a graduated cylinder.

2.5.3 Stock Complex Solutions (1000 µM)
Complex 1 (7.5 mg) and 2 (7.1 mg) were weighed out using an analytical balance
and then separately diluted to a final volume of 10 mL with dimethylformamide (DMF)
in a volumetric flask. The solution was shaken until complex was completely dissolved
and then stored at room temperature and used within 24 h of preparation.

2.5.4 Ascorbic Acid Stock Solution (2000 µM and 1000 µM)
The stock solution was prepared by first obtaining 3.52 mg and 1.76 mg of
ascorbic acid respectively diluting to a final volume of 10 mL with 5 mM Tris, 50 mM
NaCl pH 7.2 Buffer (prepared as outlined above) in a volumetric flask. Solid was
dissolved via shaking and then solutions were stored at 12°C for future use.

2.5.5 Plasmid DNA Preparation
The plasmid DNA preparation was performed by first transforming E.coli cells
via electroporation using the procedure outlined in Fox Research Lab Protocols (1-9).21
Once the cells were transformed the procedure for plasmid mini-prep was followed (Fox
Research Lab Protocols (1-12)).21 Once a purified sample of plasmid DNA was obtained
the concentration was determined using the nanodrop by following the procedure
outlined in Fox Research Lab Protocols (2-1).21
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2.5.6 Calf Thymus DNA (CT-DNA) Stock Solution
CT-DNA stock solution was prepared using the procedures outlined in Foreman
et al.20

2.5.7 Bovine Serum Albumin (BSA) Stock Solution (50 µM)
BSA stock solution was prepared using the procedures outlined in Foreman et
al.20

2.6 Biological Studies
2.6.1 DNA Cleavage and Mechanistic Studies
DNA cleavage studies were performed by preparing ten different solutions of
varying complex concentration that were composed of 5 mM Tris, 50 mM NaCl, pH 7.2
buffer, ascorbic acid at a concentration twice that of the given complex concentration,
and plasmid DNA of a constant concentration of 0.01 µg/µL. Buffer was added to ensure
each sample had a final volume of 30 µL and were prepared in accordance with the
amounts shown in Table 1. Plasmid DNA was always added last and the final solution
was mixed by pipetting up and down.

16

Table 1. Sample preparation for DNA cleavage studies using 1000 µM stock complex
solution and 1000 µM stock ascorbic acid solution.

Lane #

Complex
Concentration
(µM)

Compound
volume (µL)

DNA
volume
(µL)

[AH2]
(µM)

AH2
volume
(µL)

Buffer
volume
(µL)

1

0

0

1

0

0

29

2

100

3

1

200

6

20

3

125

3.75

1

250

7.5

17.75

4

150

4.5

1

300

9

15.5

5

175

5.25

1

350

10.5

13.25

6

200

6

1

400

12

11

7

225

6.75

1

450

13.5

8.75

8

250

7.5

1

500

15

6.5

9

275

8.25

1

550

16.5

4.25

10

300

9

1

600

18

2

The DNA cleavage mechanistic studies were performed in a similar experimental
set up was used.

Ten solutions of varying complex concentration with the same

composition shown in Table 1, except these experiments included the addition of either
L-histidine or DMSO. The volumes of each solution present in each of these samples are
outlined in Table 2 and Table 3.
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Table 2. Sample preparation for L-histidine mechanistic studies using 1000 µM stock
complex solution and 2000 µM stock ascorbic acid solution and 50 mM stock of Lhistidine.

Lane
#

Compound
(µM)

Compound
(µL)

DNA
(µg/µL)

DNA
(µL)

[AH2]
(µM)

AH2
(µL)

LHistidine
(µM)

LHistidine
(µL)

Buffer
(µL)

1

0

0

0.01

1

0

0

2000

1.2

27.8

2

100

3

0.01

1

200

3

2000

1.2

21.8

3

125

3.75

0.01

1

250

3.75

2000

1.2

20.3

4

150

4.5

0.01

1

300

4.5

2000

1.2

18.8

5

175

5.25

0.01

1

350

5.25

2000

1.2

17.3

6

200

6

0.01

1

400

6

2000

1.2

15.8

7

225

6.75

0.01

1

450

6.75

2000

1.2

14.3

8

250

7.5

0.01

1

500

7.5

2000

1.2

12.8

9

275

8.25

0.01

1

550

8.25

2000

1.2

11.3

10

300

9

0.01

1

600

9

2000

1.2

9.8

Table 3. Sample preparation for DMSO mechanistic studies using 1000 µM stock
complex solution and 2000 µM stock ascorbic acid solution and pure DMSO.

Lane #

Compound
(µM)

Compound
(µL)

DNA
(µg/µL)

DNA
volume
(µL)

[AH2]
(µM)

AH2
(µL)

DMSO
(µL)

Buffer
(µL)

1

0

0

0.01

1

0

0

3
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2

100

3

0.01

1

200

3

3

20

3

125

3.75

0.01

1

250

3.75

3

18.5

4

150

4.5

0.01

1

300

4.5

3

17

5

175

5.25

0.01

1

350

5.25

3

15.5

6

200

6

0.01

1

400

6

3

14

7

225

6.75

0.01

1

450

6.75

3

12.5

8

250

7.5

0.01

1

500

7.5

3

11

9

275

8.25

0.01

1

550

8.25

3

9.5

10

300

9

0.01

1

600

9

3

8
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Once the solutions were prepared the procedure for the DNA cleavage studies and
the mechanistic studies was identical. The solutions were left to incubate at 37°C for 2 h.
After incubation the samples were centrifuged at maximum speed in the microfuge for 5
min and then 10 µL from each sample was transferred to a separate tube. Next, 2 µL of
6X loading dye was mixed into the 10 µL samples and then the total volume of 12 µL
was loaded into a 1% agarose gel in 1X TAE running buffer. The gel was prepared using
the procedure outlined in Fox Research Lab Protocols (3-1).21 The gel was run at 80 V
for 1 h 15 min and then stained in 0.5 µg/mL EtBr for 30 min. After staining, the gel was
de-stained in deionized water for 10 min.

2.6.2 DNA Binding Ethidium Bromide (EtBr) Fluorescence Studies
DNA Binding studies were performed using the procedures outlined in Foreman
et al and Lin et al.19,20

2.6.3 Bovine Serum Albumin (BSA) Binding Fluorescence Studies
BSA binding studies were performed using the procedures outlined in Foreman et
al and Lin et al.19,20

3. Results and Discussion
3.1 Synthesis and Characterization of Ligands
The ligands PyOMe(oBt) and PyOMe(en) were synthesized by reacting 6methoxy-2-pyridine carboxaldehyde with 2-aminothiophenol and ethylene diamine,
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respectively. The reactions were carried out in methanol and the structures of these
ligands were confirmed via IR and 1H-NMR spectroscopies. The PyOMe(oBt) ligand was
formed via the condensation reaction shown in Scheme 1. The initial product formed was
typically the thiazoline intermediate shown (Scheme 1, line 2, left), however upon
oxidation in air only the final thiazole product was obtained. The two different products
can be distinguished using 1H-NMR spectroscopy based upon the disappearance of the
peaks associated with –NH and –CH shifts.22 Appendix 1 depicts the 1H-NMR spectrum
of the final thiazole product, PyOMe(oBt), which lacks both of these characteristic
thiazoline peaks and contains peaks and integration expected for the thiazole product.
The PyOMe(en) ligand was formed via the reaction shown in Scheme 2, which also
results in the formation of H2O as a byproduct. The condensation reaction could possibly
lead to both the mono- and disubstituted amine. 1H-NMR spectroscopy was used to
confirm that the product isolated was the disubstituted ligand containing two imine
groups based on the absence of a peak corresponding to NH2. The 1H-NMR spectrum of
the final product is shown in Appendix 2.
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S
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-H2

N
H

N

N

N
O

O

PyOMe(oBt)

PyOMe(Thiazoline)

Scheme 1. Reaction scheme for synthesis of PyOMe(oBt) ligand. Top: condensation of
2-aminothiophenol with 6-methoxy-2-pyridinecarboxaldehyde to form the corresponding
thiazoline. Bottom: air oxidation of the thiazoline to afford the thiazole containing
ligand.

O

N
N

NH 2

d-EtOH

+
NH 2

ethylene diamine

H

2 O

N

-H2O

N
O

O

N

6-methoxy-2-pyridinecarboxaldehyde

PyOMe(en)

Scheme 2. Reaction scheme for synthesis of PyOMe(en) ligand. Condensation of
ethylene diamine with 6-methoxy-2-pyridinecarboxaldehyde.
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3.2 Synthesis and Characterization of Cu(II) Complexes
The corresponding copper(II) complexes were obtained for both ligands.
Interestingly, two complexes were isolated for the PyOMe(oBt) ligand as a result of
reacting it with both CuCl2 and Cu(NO3)2, respectively. A single complex was isolated
for the PyOMe(en) ligand. This complex was a product of the ligand’s reaction with
Cu(NO3)2. Structures of these complexes were determined via X-ray crystallography.
Thermal ellipsoid plots showing the crystal structures of these complexes are shown in
Figure 5.
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Figure 5. Thermal ellipsoid plots (50% probability level) of complexes 1 (top left), 2 (top
right), and 3 (bottom). For complexes 2 and 3, H atoms and NO3- counter ions have been
omitted for clarity.

Synthesis of complex 1 resulted in the formation of orange-brown crystals with
block like morphology. Ligation of the ligand was confirmed by analysis of the IR
spectrum of the complex compared to the IR spectrum of the free ligand (Appendix 3).
Upon coordination, the spectrum revealed several resonances that shifted to lower energy
23

indicative of coordination (Appendix 4). X-ray analysis showed that complex 1 is a dimer
with two copper centers ligated to one ligand (N,N). The coordination sphere around each
copper is completed by two chloride ions, one terminal and one bridging. The bond
length between Cu-NPy is 2.020 Å, whereas the bond length between Cu-Nthiazole is 2.271
Å. The bond angle between these three atoms is 77.7°. The bond angle between NPy -CuCl was 91.1° and the angle between Nthiazole-Cu-Cl was 104.4° giving rise to distorted
trigonal bipyrimidal geometry around each metal center.

Synthesis of complex 2 yielded large green block like crystals. The IR spectrum
of these crystals is shown in Appendix 5. Upon coordination of the ligand, several IR
resonances shift to lower energy, indicative of coordination. The ellipsoid plot obtained
via X-ray analysis showed complex 2 is a monomer with two ligands bound to each
Cu(II) center and one O-bound nitrate with an overall +1 charge. The N4O coordination
sphere around the metal center gives rise to a distorted trigonal bipyriamidal geometry.

Synthesis of complex 3 yielded large deep blue sea urchin like crystals. Appendix
6 shows an IR spectrum of the starting ligand and Appendix 7 shows an IR spectrum of
complex 3 crystals for comparison. Similar to the complexes previously mentioned, the
IR spectrum of complex 3 revealed several resonances that shifted to lower energy upon
coordination to the metal center. X-ray analysis yielded very interesting results because
the structure of complex 3 was shown to contain two metal centers. Each copper center
was ligated to one partially hydrolyzed ligand (PyOMe(enH2)) ligand and one
unhydrolyzed ligand (PyOMe(en)) that bridged between the two metals. The geometry of
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the N5 coordination sphere around each metal center is best described as distorted square
pyriamidal. The bond lengths between Cu-NPy were 2.023 and 1.962 Å with an angle of
82.5°. The bond lengths between Cu-Nen were 2.017, 2.097, and 2.246 Å with angles of
169.1° and 77.3°. The bond angle between Nen-Cu-NPyOMe was 102.0°.

The observed structural differences between complexes 1 and 2 demonstrate the
impact that the starting metal has on the overall structure of the complex. However, for
complex 3 there were inconsistencies between the molecular weight indicated by the Xray crystal structure and the elemental analysis data. This made it unclear whether the
complex was undergoing the same extent of hydrolysis every time the reaction was
carried out. Experimentation with this complex is still ongoing, however, until the
molecular weight and crystal structure data match the elemental analysis for the bulk,
complex 3 cannot be tested for biological activity.

3.2 DNA Cleavage Studies
DNA is a common target of chemotherapy drugs because of its key role in cellular
proliferation. Cells require DNA that is both intact and accessible to replication
machinery in order to divide. Cancer cells are particularly impacted by reagents that
target DNA because of their characteristic rapid proliferation rates.9 While some
complexes’ mode of action involves permanent binding to the DNA, copper complexes
are known for their ability to cleave DNA. The ability of a compound to induce DNA
cleavage is also known as nuclease activity. One measure that was used to assess these
complexes’ biological activity and potential as a chemotherapeutic agent was nuclease
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activity. In particular, the biological assays were used to analyze how the differing
structures impact the overall biological activity.

In order to test the complexes’ ability to cleave DNA the complexes were
incubated with plasmid DNA in the presence of ascorbic acid. Complex concentrations
ranged from 100 to 300 µM and were increased in 25 µM increments. A blank was also
run without any complex present. Once the samples were incubated with the complex
agarose gel-electrophoresis was used to separate the DNA based on size. Plasmid DNA
can exist in several different conformations: super-coiled (SC), single-nicked (SN), and
double-nicked (DN). Each of these conformations travels through the gel matrix at
different rates and can therefore be distinguished from each other. This is important for
these studies because each form of the DNA represents a different extent of cleavage;
SC-DNA represents DNA that has not been cleaved by the complex, SN-DNA represents
DNA that has been cut by the complex once, and DN-DNA represents DNA that has been
cut by the complex twice. The cleavage studies, as outlined above, were carried out using
complexes 1 and 2. Figure 6 shows representative gels from these cleavage studies.
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Figure 6. Pictures of gels from DNA cleavage studies Complex 1 (top) complex 2
(bottom). Reactions carried out at the concentrations of complex indicated below each gel
in the presence of twice the concentration of ascorbic acid. Samples were incubated for 2
h at 37°C.

The gels showed that SN and DN-DNA were present in lanes that corresponded to
samples incubated with complex. This indicated that the complexes are able to cleave
DNA. Next, concentration dependent cleavage was determined. Band density analysis
was used to determine the relative percentages of DNA in each lane on the gel. Since
each lane corresponded to a given concentration of complex, complex concentration was
correlated with percentages of DNA in each form. Bar graphs that show the percentages
of DNA in each form at every concentration of complex 1 and 2 tested are depicted in
Figure 7.
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Figure 7. Relative percentages of DNA forms for concentration dependent cleavage
studies. Complex 1 (top) complex 2 (bottom).
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The percentages of DNA in the SN and DN forms are indicative of the percentage
of DNA that was cleaved by the complex. The graphs show that even at the lowest
concentrations of complex 1 and 2 all of the DNA has at least been converted into the SN
form. This indicates that the complex cleaved all of the DNA at least once. The
percentage of DNA in the DN form is equivalent to the percentage of DNA that was
cleaved by the complex twice. The graph also shows that as the concentration of complex
increased the percentage of DN-DNA formed also increased. This trend indicates that
both complex 1 and 2 cleave DNA in a concentration-dependent manner, because the
amount of cleavage is directly related to the concentration of complex. Comparison of the
two graphs shows that more DN-DNA was formed in the presence of complex 2 than in
the presence of complex 1 at the same concentration. This indicates that complex 2 acts
as more efficient nuclease than complex 1. When comparing the structures of these two
complexes the differences in reactivity can potentially be attributed to the positive charge
on complex 2. The DNA backbone is negatively charged so the electrostatic interaction
between the DNA and the positively charged complex (2) may be stronger than the
interaction between DNA and neutral compound (1).

3.3 DNA Cleavage Mechanistic Studies
Since it was determined that the complexes were able to cleave DNA, it was of
interest to determine the mechanism of this cleavage. Copper complexes are known to
cleave DNA via either a hydrolytic or oxidative mechanism.23,24 The oxidative
mechanism requires the production of radical oxygen species (ROS).25 Common ROS
that have been implicated in this type of cleavage include singlet oxygen (1O2), hydroxyl
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radical (OH), and super oxide.25,26 The hydrolytic mechanism requires water to induce
nucleophilic attack of the DNA phosphate backbone.24 Initial cleavage studies showed
that in the presence of water but the absence of a reductant (ascorbic acid) needed to
induce a Cu(II)/Cu(I) redox couple that generates ROS2, the complexes did not exhibit
cleavage. This indicates that a hydrolytic mechanism is not invoked in the DNA cleavage
exhibited by complexes 1 and 2. In order to ascertain if an oxidative mechanism was
followed, DNA cleavage reactions were carried out with the addition of known radical
oxygen scavengers. These scavengers remove all the ROS of a particular type from
solution. The underlying motivation for conducting these studies is that if the removal of
a particular ROS impacts reactivity, then that implicates that ROS in the mechanism as
well as confirms that an oxidative mechanism is followed.

Studies were carried out using L-histidine, which is a known singlet oxygen (1O2)
scavenger.27 These reaction were carried out by incubating the DNA with varying
concentration of complex in the presence of a constant concentration of L-histidine (Fig.
8). The gels show that single nicked DNA was formed but DN-DNA was not. This
contrasts with the results of the initial cleavage studies carried out in the absence of
scavenger, which did show the production of DN-DNA. Figure 9 shows bar graph
representations of the relative amounts of SC and SN-DNA at each concentration of
complex 1 and 2. The graphs show quantitatively that DN-DNA was not formed and the
percentage of SN-DNA was decreased when compared with initial cleavage studies. The
observed decrease in DNA cleavage in the presence of L-histidine indicates that 1O2 plays
a mechanistic role in the cleavage of DNA by complex 1 and 2. The fact that SN-DNA
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was still formed but in lower quantities indicated that the 1O2 species may play a more
minor role in the conversion of SC-DNA to SN-DNA. The complete inhibition of the
formation of DN-DNA indicated that 1O2 plays a major role in the conversion of SNDNA to DN-DNA.

Figure 8. Pictures of gels from DNA cleavage mechanistic studies using L-histidine.
Complex 1 (top) complex 2 (bottom). Reactions carried out at the concentrations of
complex indicated in the presence of twice the concentration of ascorbic acid and a
constant L-histidine concentration of 2 mM. Samples were incubated for 2 h at 37°C.
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Figure 9. Relative percentages of DNA forms for L-histidine mechanistic studies.
Complex 1 (top) complex 2 (bottom) (note: this plot is an average of two runs).
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Additional mechanistic studies were conducted using DMSO, which is a known
hydroxyl radical scavenger.26 Representative gels of these studies are shown in Figure 10.
These gels look very similar to the gels produced from the cleavage studies without any
inhibitor, in that SN and DN-DNA forms are seen in every lane that corresponds to
complex. The graphical representations, shown in Figure 11, indicated that there was no
observable reactivity difference when DMSO was added into the reaction mixture. This
indicates that OH species do not play a role in the DNA cleavage mechanism for either
complex 1 or 2.

Figure 10. Pictures of gels from DNA cleavage mechanistic studies using DMSO.
Complex 1 (top) complex 2 (bottom). Reactions carried out at the concentrations of
complex indicated in the presence of twice the concentration of ascorbic acid and a
constant DMSO concentration of 10% by volume. Samples were incubated for 2 h at
37°C.
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Figure 11. Relative percentages of DNA forms for DMSO mechanistic studies. Complex
1 (top) complex 2 (bottom).
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The role of ROS in the mechanism indicated that both complexes react via an
oxidative mechanism Based on the mechanistic studies it was concluded that 1O2 plays an
important mechanistic role in the cleavage of DNA by complexes 1 and 2, but that OH
does not play a role in either complex’s mechanism of action. Since neither scavenger
was able to completely inhibit nuclease activity, additional mechanistic studies need to be
carried out to determine if other ROS, such as superoxide, are involved in the mechanism.

3.4 DNA Binding Studies
The exhibited nuclease activity of complexes 1 and 2 indicate that they interact
with DNA. However, it is unclear what type of interaction(s) is (are) occurring. One of
the goals of this project was to carry out DNA binding studies using ethidium bromide
(EtBr) in order to determine if the complexes intercalate DNA. Compounds that exhibit
DNA intercalation are able to insert themselves between the DNA bases. EtBr is a known
DNA intercalating agent with a very strong binding affinity, with Kds-DNA=130E104 M-1
(the binding constant to double-stranded DNA).28 One of the main reasons EtBr can be
used in these types of studies is because the EtBr-DNA complex has a characteristic
fluorescence.29,30 In the presence of a reagent that can competitively intercalate into DNA
a decrease in this fluorescence is observed because some of the EtBr is displaced from
the DNA where bulk solvent quenches the florescence signal.30,31 If a decrease in
fluorescence is observed in the presence of complex within a solution containing EtBr
and DNA then it can be concluded that the complex is an intercalating agent.
Additionally, the amount of fluorescence quenching can be mathematically related to the
complex’s DNA binding constant (Kbind).
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Solutions containing a constant concentration of EtBr and CT-DNA were
prepared with a complex concentration range of 0-105 µM. However, both complex 1
and 2 formed a cloudy precipitate when added into the solution mixture. Since
fluorescence data can only be collected with a clear solution, these studies are still
inconclusive. Some preliminary work has been conducted which indicates that increasing
the overall percentage of DMF in these solutions may prevent the formation of precipitate.
Initial measurements using complex 2 with solution containing 30% DMF using an
incubation time of 30 min did not show any discernable trend. Further studies are needed
to determine if increasing the incubation time would yield different results, because the
initial incubation time used may not have been sufficient for complete binding to occur.

3.5 Protein Binding Studies
Another important aspect to consider when designing chemotherapeutic agents is
their ability to be transported throughout the body because they must reach the site of
cancer in order to be effective. Human Serum Albumin (HSA) is the most abundant
protein in human blood serum.32 Therefore, binding of potential chemotherapeutic agents
to this protein is of interest when trying to determine if a compound has the potential to
be circulated throughout the body. Additionally, some studies have found that serum
proteins accumulate in tumor tissue so binding these proteins may help the complex
aggregate in the desired target region.33 Bovine serum albumin is an analog to HSA that
is found in bovine.34 Compounds’ binding constants to BSA have also been related to
their distribution throughout, and excretion from, the body.35 BSA has a characteristic
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fluorescence when it is free in solution and this fluorescence decreases when it is bound
to something that decreases the exposure of its tryptophan residues.32 Similarly to the
EtBr studies previously described, the amount of fluorescence quenching can be
measured and used to determine a binding constant. In order to extract the binding
constant of complex 1, solutions were prepared with varying concentration of complex in
the presence of a constant concentration of BSA and fluorescence measurements were
taken. The fluorescence measurements showed that complex 1 is capable of fluorescing
in the observed region in the absence of BSA. Figure 12 shows the fluorescence of
complex 1 in buffer with 30% DMF at concentrations from 0-110 µM with an excitation
wavelength 280 nm over a range of 290-450 nm. The inherent fluorescence of the
complex interfered with attempts to measure a change in the fluorescence of BSA at these
wavelengths. Further studies should be carried out to determine if a different excitation
wavelength can be used and to determine if complex 2 exhibits the same fluorescence.

Figure 12. Emission spectra of complex 1 in buffer with 30% DMF.
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3.6 Conclusions
The complexes Cu(PyOMe(oBt))Cl2 (1), [Cu(PyOMe(oBt)2(NO3)]NO3 (2), and
[Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4

(3)

were

successfully

synthesized

and

characterized. The observed structural differences between complex 1 and 2 were a result
of varying the starting metal. Complex 3 demonstrated an interesting ability to selfhydrolyze, however it is still uncertain if the extent of this hydrolysis of the ligand
backbone is consistent in each synthetic reaction. It has been demonstrated that
complexes 1 and 2 exhibit concentration dependent nuclease activity. Additionally, 2 was
able to act as a more efficient nuclease compared to complex 1. The differences in
reactivity can likely be attributed to the complexes differing overall charges. Complex 2
has an overall positive charge, whereas complex 1 is neutral. Mechanistic studies showed
that both complex 1 and 2 cleave DNA via an oxidative mechanism and 1O2 plays a key
role in this mechanism. Additionally, these studies showed that OH does not play a role
in DNA cleavage by these complexes. There are several additional studies that are needed
in order to fully characterize the biological activity of these complexes and make
subsequent comparisons. These studies include additional mechanistic studies of other
ROS, DNA intercalation studies using EtBr, and BSA binding studies.
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Appendix 3. IR spectrum of PyOMe(oBt) ligand.
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Appendix 4. IR spectrum of Cu(PyOMe(oBt))Cl2.
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Appendix 5. IR spectrum of [Cu(PyOMe(oBt)2(NO3)]NO3.
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Appendix 6. IR spectrum of PyOMe(en).
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Appendix 7. IR spectrum of [Cu2(PyOMe(en))(PyOMe(enH2)2](NO3)4.
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